Search Results
Nov 10, 2025, 08:00 ET Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare
More news about: TiumBio
Nov 10, 2025, 08:00 ET Williams Cancer Institute Presents Data on Combined Pulsed Electrical Field Ablation and Intratumoral Immunotherapy at SITC 2025
ablation plus intratumoral immunotherapy for head and neck squamous cell carcinoma" were presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, held in San Diego, California. "Our findings reinforce the potential of combining precision-based local ablation
More news about: Williams Cancer Institute
Nov 10, 2025, 07:00 ET Compugen Reports Third Quarter 2025 Results
COM701 maintenance therapy in patients with platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027 SITC 2025 – Compugen presented Phase 1 trial design for GS-0321 (COM503), licensed to Gilead Partner AstraZeneca shared promising
More news about: Compugen Ltd.
Nov 10, 2025, 03:30 ET Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
2026 Poster presentation of AERIAL trial presented at SITC 2025 Annual Meeting LONDON,
More news about: Leucid Bio
Nov 07, 2025, 13:30 ET Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers
Two presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting highlight promising new clinical trial results NEW BRUNSWICK, N.J.,
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
following EGFR-TKI progression, were selected as a "Late-Breaking Abstract" (LBA) for the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in National Harbor, Maryland, USA. Professor Xiuning Le from MD Anderson Cancer Center presented these findings to a global audience during an
More news about: Akeso, Inc.
Nov 07, 2025, 11:30 ET Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. The results demonstrated that AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory
More news about: Akeso, Inc.
Nov 07, 2025, 09:05 ET Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit's AI-powered digital pathology technologies—Lunit
More news about: Lunit
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
evaluating MT-302, an mRNA-LNP-encoded TROP2-targeted in vivo CAR therapy in patients with advanced solid tumors, at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting.
More news about: CREATE Medicines, Inc.
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland. Both datasets were accepted for late-breaking poster presentations, highlighting the program's
More news about: HanchorBio Inc.
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
The data were presented in a late-breaking clinical oral presentation at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This marks Invikafusp alfa's fifth major oral presentation, underscoring continued external interest and excitement around the
More news about: Marengo Therapeutics
Nov 07, 2025, 09:00 ET Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
1 data on DOC1021, a patient-specific dendritic cell therapy, in pancreatic ductal adenocarcinoma (PDAC) at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, being held November 7-9 in National Harbor, MD.
More news about: Diakonos Oncology
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
evasive iPSC therapies toward the clinic in 2026, and today announces its first data presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN FRANCISCO
More news about: Shinobi Therapeutics
Nov 06, 2025, 10:00 ET ELEPHAS BIOSCIENCES RAISES $40M TO ACCELERATE COMMERCIALIZATION OF ITS LIVE TUMOR PROFILING PLATFORM
Galon and fellow Elephas advisory board member Janis Taube, M.D., will be joining Elephas at the upcoming Societies for the Immunotherapy in Cancer (SITC) Annual Meeting on November 8, 2025, in National Harbor, MD (
More news about: Elephas
Nov 06, 2025, 08:00 ET Pictor Labs Expands AI Pathology Portfolio with Launch of ClearStain™ for Digital Sequencing Workflows
found them visually comparable in 99-100% of regions reviewed. ClearStain™ will debut at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9 at the Gaylord National Resort & Convention Center in National Harbor, Maryland. Attendees can visit
More news about: Pictor Labs
Nov 05, 2025, 16:07 ET Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
data for several human cancer types expressing truncated core 2 O-glycans will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 7th, 2025, National Harbor, MD, USA.
More news about: Precision Biologics
Nov 05, 2025, 08:30 ET Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
announced that research and expertise from across its network will be showcased at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5–9 in National Harbor, Maryland. PICI leaders, investigators and collaborators are contributing to 80 posters, presentations and discussions
More news about: Parker Institute for Cancer Immunotherapy
Nov 05, 2025, 08:00 ET Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings
CAR T company developing a novel KIR-CAR platform technology, today announced its participation at the upcoming Society of Immunotherapy in Cancer (SITC) 2025 Annual Meeting and American Society of Hematology (ASH) 2025 Annual Meeting. The company will present new preclinical and translational data supporting
More news about: Verismo Therapeutics
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
immunotherapeutic fusion protein, has been accepted for presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 5-9, 2025, in National Harbor, Maryland. Featured in a poster presentation, the data highlight HCB301's differentiated design
More news about: HanchorBio Inc.
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Availability at SITC 2025 Bio-Techne's full spatial biology portfolio—including the new ProximityScope™ assay and the extended SPYRE™ portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be
More news about: Bio-Techne Corporation
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
survival (PFS) not yet reached and projected to exceed 12 months. The summary of this Phase I study was selected as an oral presentation at the upcoming SITC Annual Meeting, and the results will be presented on November 8, 2025. "Next-generation IL-2 agents have been a major focus of
More news about: iLeukon Therapeutics
Nov 03, 2025, 16:05 ET AAVivo, Inc. to Present at Society for Immunotherapy of Cancer 2025
enable in vivo generation of CAR-T cells was accepted for presentation at SITC 2025," said Haifeng Chen, Ph.D. Chief Technology Officer & Founder of AAVivo. "Having this research accepted for presentation at SITC, one of the preeminent oncology conferences, showcases the breadth of AAVivo's patented
More news about: AAVivo, Inc.
Nov 03, 2025, 08:00 ET CREATE Medicines to Present Late-Breaking Clinical Data on MT-302 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
tunable CAR expression for potent anti-tumor activity. Additional details will be presented during the SITC Annual Meeting and will be available on the SITC website,
More news about: CREATE Medicines, Inc.
Oct 31, 2025, 10:00 ET The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at its 40th Anniversary Annual Meeting
About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 31, 2025, 07:00 ET Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers
& immunology (I&I), today announced that it will present a late-breaking oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland.
More news about: Marengo Therapeutics